Sorrento Therapeutics, Inc.
4955 Directors Pl.
About Sorrento Therapeutics, Inc.
368 articles about Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. Announces a Presentation on Cynviloq™ at the AACR Conference on Advances in Ovarian Cancer Research: From Concept to Clinic
Sorrento Therapeutics, Inc. Secures Rights to Biomiga Diagnostics' Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
Sorrento Therapeutics, Inc. Completes IgDraSol Merger
Sorrento Therapeutics, Inc. to Present at Two Healthcare Conferences
Sorrento Therapeutics, Inc. and IGDRASOL Proceed with Development of Cynviloq™ under 505(b)(2) Bioequivalence Regulatory Pathway
Sorrento Therapeutics, Inc. Announces Reverse Split of Common Stock
Sorrento Therapeutics, Inc. and Ben-Gurion University of the Negev Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
Sorrento Therapeutics, Inc. and IGDRASOL Will Present Preliminary Phase III Data Analysis for Cynviloq at the 4th International Nanomedicine Conference in Sydney, Australia
Sorrento Therapeutics, Inc. Presents Preclinical Data of its Fully Human Antibody Programs Targeting Anti-PD-L1 and Anti-PD-1 at the 8th Annual Next Generation Protein Therapeutics Summit
Sorrento Therapeutics, Inc. and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Sorrento Therapeutics, Inc. Receives Frost & Sullivan's 2013 Global Investment Opportunity Award in Oncology
Sorrento Therapeutics, Inc. to Present at the Jefferies and Co. 2013 Global Healthcare Conference in New York City
Sorrento Therapeutics, Inc. and IGDRASOL Present Phase I Clinical Data for the Combination of CynviloqTM (paclitaxel polymeric micelle) plus gemcitabine for Treatment of Advanced Pancreatic Cancer at American Society of Clinical Oncology 2013 (booth #2090
Sorrento Therapeutics, Inc. Announces Its Approach to Developing Human Antibody Therapeutics Against MRSA Receives Continued Support From the National Institute of Allergy and Infectious Diseases
Sorrento Therapeutics, Inc. and IGDRASOL Announce the Acquisition of Exclusive Distribution Rights to Cynviloq™ for the European Union
Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
Sorrento Therapeutics, Inc. and IGDRASOL Announce Three Presentations on Cynviloq&0153 (IG-001; Paclitaxel Polymeric Micelle) at the American Association for Cancer Research (AACR) Meeting
Sorrento Therapeutics, Inc. Signs Exclusive Option to Acquire IGDRASOL
Sorrento Therapeutics, Inc. Acquires Rights to Produce Recombinant Intravenous Immunoglobulins (rIVIG)
Sorrento Therapeutics, Inc. Awarded Third Phase I STTR Grant